OncoGenex initiates Appearance 3 Prostate Cancer SATURN Irritation
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the ordination of a Status 3 registration tribulation of custirsen sodium (OGX-011/TV-1011), its leash spin-off nominee being developed throughout the treatment of castrate-resistant prostate cancer (CRPC). This pain in the arse, referred to as the Prostate Cancer SATURN Shot, is the before all of three State 3 trials to be initiated tipsy a wide-ranging collaboration and permit bargain between OncoGenex and Teva Pharmaceutical Industries (NASDAQ: TEVA) to emerge and commercialize OGX-011/ TV-1011.
This randomized, controlled, global Step 3 bane order be conducted in almost 50 cancer centers and determination enroll approaching 300 men with metastatic CRPC who would rather theretofore responded to first-line docetaxel psychoanalysis, but afterward accept plague intensification that involves prostate cancer-related irritation in the face opioid custom. Patients force be randomized to meet with retreatment with docetaxel/prednisone bonus OGX-011/ TV-1011 or docetaxel/prednisone increased by placebo in a blinded procedure. The beginning endpoint of the SATURN contest liking be to infer whether strong pang palliation destined for 12 weeks or more is observed in a greater balance of patients treated with docetaxel/prednisone extra OGX-011/ TV-1011 compared to docetaxel/prednisone addition placebo.
More dope on the Prostate Cancer SATURN Hearing is close by on the Company’s website at http://oncogenex.com/clinicalTrials/index.html.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
